## First-Line Chemotherapy for Epithelial Ovarian Cancer **Key Point:** Paclitaxel (Taxol) and carboplatin is the gold-standard first-line regimen for advanced epithelial ovarian cancer post-surgery. ### Rationale for Paclitaxel + Carboplatin 1. **Evidence Base** - Established by the GOG-111 trial and subsequent meta-analyses - Superior response rates and overall survival compared to cisplatin-based monotherapy - Carboplatin preferred over cisplatin due to better tolerability and equivalent efficacy 2. **Mechanism** - **Paclitaxel:** Microtubule stabilizer; induces apoptosis - **Carboplatin:** Platinum-based alkylating agent; DNA cross-linking - Synergistic cytotoxic effect when combined 3. **Dosing & Schedule** - Paclitaxel: 175 mg/m² IV over 3 hours - Carboplatin: AUC 5–6 IV - Administered every 3 weeks for 6 cycles ### Current Practice Enhancements | Addition | Indication | Benefit | |----------|-----------|----------| | Bevacizumab (Avastin) | Stage III–IV disease | Improved PFS; consider in high-risk patients | | PARP inhibitors (maintenance) | BRCA mutation or HRD-positive | Extended PFS post-chemotherapy | | Dose-dense paclitaxel | Selected cases | May improve outcomes in some cohorts | **High-Yield:** Paclitaxel + carboplatin remains the backbone of first-line therapy; bevacizumab and PARP inhibitors are added based on molecular features and stage, not as replacements. **Clinical Pearl:** Carboplatin is preferred over cisplatin in ovarian cancer because it has less nephrotoxicity and neurotoxicity while maintaining equivalent anti-tumor activity.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.